These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9196128)

  • 1. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
    Ozols RF
    J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
    J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line therapy.
    Nurs Stand; 1997 Feb; 11(21):28. PubMed ID: 9110778
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
    Choi CH; Lee YY; Song TJ; Park HS; Kim MK; Kim TJ; Lee JW; Lee JH; Bae DS; Kim BG
    Cancer; 2011 May; 117(10):2104-11. PubMed ID: 21523722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
    Saltz L; Janik JE
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of platinum-resistant ovarian cancer].
    Onishi Y; Nakamura T; Hatae M
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical studies of topotecan.
    Broom C
    Ann N Y Acad Sci; 1996 Dec; 803():264-71. PubMed ID: 8993520
    [No Abstract]   [Full Text] [Related]  

  • 10. Trial of topotecan as first-line treatment for ovarian cancer announced.
    Oncology (Williston Park); 1996 Mar; 10(3):416. PubMed ID: 8820452
    [No Abstract]   [Full Text] [Related]  

  • 11. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
    Markman M
    Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
    [No Abstract]   [Full Text] [Related]  

  • 12. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].
    Yahagi N; Kobayashi Y; Ohara T; Kondo H; Suzuki N; Kiguchi K; Ishizuka B
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2583-6. PubMed ID: 20009459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of a second instance of carcinoma of the ovary].
    Giaccone G; Clerico M; Donadio M; Calciati A
    Minerva Ginecol; 1984 Apr; 36(4):209-12. PubMed ID: 6462524
    [No Abstract]   [Full Text] [Related]  

  • 15. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
    Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
    Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.
    Bryant CS; Kumar S; Spannuth W; Shah JP; Munkarah AR; Deppe G; Alvarez RD; Morris RT
    Arch Gynecol Obstet; 2011 Feb; 283(2):361-7. PubMed ID: 20383771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
    Wethington SL; Wright JD; Herzog TJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):819-31. PubMed ID: 18471053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
    Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
    Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
    J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
    [No Abstract]   [Full Text] [Related]  

  • 20. Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
    Cass I; Kuo DY; Fields AL; Runowicz CD; Goldberg GL
    Gynecol Oncol; 1998 May; 69(2):175-8. PubMed ID: 9600828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.